Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: A Fondazione Italiana Linfomi phase II study

Emilio Iannitto, Stefano Luminari, Claudio Tripodo, Salvatrice Mancuso, Marina Cesaretti, Luigi Marcheselli, Francesco Merli, Caterina Stelitano, Angelo Michele Carella, Alberto Fragasso, Elisa Montechiarello, Giuseppina Ricciuti, Alessandro Pulsoni, Marco Paulli, Vito Franco, Massimo Federico

Research output: Contribution to journalArticle

Abstract

Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.

Original languageEnglish
Pages (from-to)3281-3287
Number of pages7
JournalLeukemia and Lymphoma
Volume56
Issue number12
DOIs
Publication statusPublished - Dec 2 2015

Fingerprint

Vincristine
Prednisone
Cyclophosphamide
Lymphoma
Splenectomy
Sepsis
Pneumonia
Therapeutics
Neutropenia
Disease-Free Survival
Disease Progression
liposomal doxorubicin
Rituximab
Survival
Infection
Neoplasms

Keywords

  • first line
  • rituximab
  • Splenic marginal zone lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma : A Fondazione Italiana Linfomi phase II study. / Iannitto, Emilio; Luminari, Stefano; Tripodo, Claudio; Mancuso, Salvatrice; Cesaretti, Marina; Marcheselli, Luigi; Merli, Francesco; Stelitano, Caterina; Carella, Angelo Michele; Fragasso, Alberto; Montechiarello, Elisa; Ricciuti, Giuseppina; Pulsoni, Alessandro; Paulli, Marco; Franco, Vito; Federico, Massimo.

In: Leukemia and Lymphoma, Vol. 56, No. 12, 02.12.2015, p. 3281-3287.

Research output: Contribution to journalArticle

Iannitto, E, Luminari, S, Tripodo, C, Mancuso, S, Cesaretti, M, Marcheselli, L, Merli, F, Stelitano, C, Carella, AM, Fragasso, A, Montechiarello, E, Ricciuti, G, Pulsoni, A, Paulli, M, Franco, V & Federico, M 2015, 'Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: A Fondazione Italiana Linfomi phase II study', Leukemia and Lymphoma, vol. 56, no. 12, pp. 3281-3287. https://doi.org/10.3109/10428194.2015.1029925
Iannitto, Emilio ; Luminari, Stefano ; Tripodo, Claudio ; Mancuso, Salvatrice ; Cesaretti, Marina ; Marcheselli, Luigi ; Merli, Francesco ; Stelitano, Caterina ; Carella, Angelo Michele ; Fragasso, Alberto ; Montechiarello, Elisa ; Ricciuti, Giuseppina ; Pulsoni, Alessandro ; Paulli, Marco ; Franco, Vito ; Federico, Massimo. / Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma : A Fondazione Italiana Linfomi phase II study. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 12. pp. 3281-3287.
@article{a4bcead582014eddafb9346fa8cd41d2,
title = "Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: A Fondazione Italiana Linfomi phase II study",
abstract = "Rituximab {\circledR} provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84{\%}. The 6-year progression-free survival and overall survival were 54{\%} and 72{\%}, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26{\%}; grade ≥ 3 infections: 8{\%}). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.",
keywords = "first line, rituximab, Splenic marginal zone lymphoma",
author = "Emilio Iannitto and Stefano Luminari and Claudio Tripodo and Salvatrice Mancuso and Marina Cesaretti and Luigi Marcheselli and Francesco Merli and Caterina Stelitano and Carella, {Angelo Michele} and Alberto Fragasso and Elisa Montechiarello and Giuseppina Ricciuti and Alessandro Pulsoni and Marco Paulli and Vito Franco and Massimo Federico",
year = "2015",
month = "12",
day = "2",
doi = "10.3109/10428194.2015.1029925",
language = "English",
volume = "56",
pages = "3281--3287",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma

T2 - A Fondazione Italiana Linfomi phase II study

AU - Iannitto, Emilio

AU - Luminari, Stefano

AU - Tripodo, Claudio

AU - Mancuso, Salvatrice

AU - Cesaretti, Marina

AU - Marcheselli, Luigi

AU - Merli, Francesco

AU - Stelitano, Caterina

AU - Carella, Angelo Michele

AU - Fragasso, Alberto

AU - Montechiarello, Elisa

AU - Ricciuti, Giuseppina

AU - Pulsoni, Alessandro

AU - Paulli, Marco

AU - Franco, Vito

AU - Federico, Massimo

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.

AB - Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.

KW - first line

KW - rituximab

KW - Splenic marginal zone lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84948717353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948717353&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1029925

DO - 10.3109/10428194.2015.1029925

M3 - Article

C2 - 25791121

AN - SCOPUS:84948717353

VL - 56

SP - 3281

EP - 3287

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -